NEW YORK, Sept. 17 — Agilent and Incyte said today that they would expand an existing licensing agreement to enable Agilent to offer a more comprehensive range of catalog and custom microarrays using Incyte’s gene patent portfolio and genomic databases. Using Incyte’s LifeSeq products, Agilent said it would develop highly specific cDNA- and oligonucleotide-based microarrays.
The companies said that the expanded agreement would enhance the development of custom arrays for customers of Agilent’s Technology Access Program who are subscribers to Incyte’s databases or who wish to include LifeSeq sequences or Incyte-patented sequences in their custom arrays.
Incyte said it would receive additional license fees as well as royalties on sales of microarrays that Agilent develops using Incyte’s patent portfolio and technology.
Roy Whitfield, CEO of Incyte, said in a statement that the expansion of the companies' agreement should “enhance Agilent’s ability to capture a significant portion of the microarray market recently estimated by Frost and Sullivan to be approximately $2.6 billion by 2004.” Whitfield added that the product line expansion would benefit Incyte “through greater licensing and potential royalty revenues and by increasing the demand for our databases among Agilent array customers.”
In August, Agilent posted a third-quarter operating loss said that it would cut 4,000 jobs, or 9 percent of its work force, by mid-2002.